Literature DB >> 10500328

[Immunomodulation of recurrent urinary tract infections with Urvakol vaccine].

D Koukalová1, R Reif, V Hájek, Z Mucha, J Veselý, M Viktorinová, I Lochman.   

Abstract

The authors present the results of the URVAKOL vaccine use in clinical practice. The vaccine was administered in the treatment of recurrent cystitis, persistent lower urinary tract infection, chronic pyelonephritis and prostatovesiculitis. The clinical efficacy of the vaccine was assessed by detection of bacteria and leukocytes in the urine, subjective complaints, skin tests and the assessment of selected specific and nonspecific immunity parameters in the urine and saliva. Significantly positive clinical and laboratory responses were observed in patients with uncomplicated cystitis. In the group of persistent urinary tract infections excellent responses were detected in one half of the patients. The remainder half stated disappearance of subjective complaints, but with persistence of pyuria or bacteriuria. Similar results of "improvement" were observed in 10 patients with chronic pyelonephritis. There were no changes of the clinical state observed in patients with chronic prostatitis. (Tab. 5, Fig. 2, Ref. 7.)

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10500328

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  3 in total

1.  Vaccine Development for the Prevention of Urinary Tract Infections.

Authors:  Walter J. Hopkins; David T. Uehling
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

2.  UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.

Authors:  Christina A Sarkissian; Christopher J Alteri; Harry L T Mobley
Journal:  Vaccine       Date:  2019-07-15       Impact factor: 3.641

Review 3.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.